Literature DB >> 6812118

Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine.

K T Finnegan, G Ricaurte, L S Seiden, C R Schuster.   

Abstract

The long-term neurochemical and behavioral effects of repeated d-methylamphetamine (d-MA) administration were investigated using four male rhesus monkeys trained to lever-press for food on a DRL-40s schedule of reinforcement. Dose-response curves for d-MA (0.0625-2.0 mg/kg), apomorphine (0.025-0.4 mg/kg), and haloperidol (0.005-0.04 mg/kg) on responding showed that repeated d-MA administration (0.5-16.0 mg/kg/day) decreased sensitivity to d-MA and to apomorphine but increased sensitivity to haloperidol. At 3-6 months after the last injection of d-MA, a 48.1% decrease in caudate dopamine (DA) was observed, with the frontal cortex, midbrain, and pons-medulla showing no significant change. A trend toward increasing concentrations of norepinephrine was noted in the same brain areas, but only in the frontal cortex did this change reach significance. Specific binding of 3H-spiroperidol to caudate membrane preparations was not changed, while the Vmax of the caudate DA re-uptake process declined 32%, with no change in Km. These results suggest that exposure of DA neurons in the caudate nucleus to high concentrations of d-MA can lead to nerve terminal degeneration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812118     DOI: 10.1007/bf00436098

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Timing behavior during prolonged treatment with dl-amphetamine.

Authors:  C R SCHUSTER; J ZIMMERMAN
Journal:  J Exp Anal Behav       Date:  1961-10       Impact factor: 2.468

2.  Biological disposition of apomorphine. III. Kinetics of metabolism of apomorphine and role of the liver in its biotransformation.

Authors:  P N KAUL; E BROCHMANN-HANSSEN; E L WAY
Journal:  J Pharm Sci       Date:  1961-03       Impact factor: 3.534

3.  Enhancement of methylphenidate-induced stereotypies by repeated administration of neuroleptis.

Authors:  B Fjalland; I Moller Nielsen
Journal:  Psychopharmacologia       Date:  1974-01-11

4.  An experimental model of tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

5.  Contingent tolerance to the anorexigenic effects of amphetamine.

Authors:  P L Carlton; D L Wolgin
Journal:  Physiol Behav       Date:  1971-08

6.  The pharmacological and anatomical substrates of the amphetamine response in the rat.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

7.  Distribution and occurrence of amphetamine and p-hydroxyamphetamine in tissues of the rat after injection of d-amphetamine sulfate.

Authors:  T J Danielson; A A Boulton
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

8.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

9.  Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain.

Authors:  G A Ricaurte; R W Guillery; L S Seiden; C R Schuster; R Y Moore
Journal:  Brain Res       Date:  1982-03-04       Impact factor: 3.252

10.  TACHYPHYLAXIS TO SOME SYMPATHOMIMETIC AMINES IN RELATION TO MONOAMINE OXIDASE.

Authors:  M D DAY; M J RAND
Journal:  Br J Pharmacol Chemother       Date:  1963-08
View more
  15 in total

1.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 2.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

3.  Functional consequences following methamphetamine-induced neuronal damage.

Authors:  M J De Vito; G C Wagner
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms.

Authors:  C Demellweek; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Behavioural influences on benzodiazepine tolerance: when do they occur and what do they mean?

Authors:  A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine.

Authors:  W A Cass
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 7.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

8.  Brain serotonin transporter in human methamphetamine users.

Authors:  Stephen J Kish; Paul S Fitzmaurice; Isabelle Boileau; Gregory A Schmunk; Lee-Cyn Ang; Yoshiaki Furukawa; Li-Jan Chang; Dennis J Wickham; Allan Sherwin; Junchao Tong
Journal:  Psychopharmacology (Berl)       Date:  2008-10-08       Impact factor: 4.530

9.  Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults.

Authors:  Mariana Cherner; Paola Suarez; Corinna Casey; Robert Deiss; Scott Letendre; Thomas Marcotte; Florin Vaida; J Hampton Atkinson; Igor Grant; Robert K Heaton
Journal:  Drug Alcohol Depend       Date:  2009-10-07       Impact factor: 4.492

10.  The effects of methamphetamine on core body temperature in the rat--part 1: chronic treatment and ambient temperature.

Authors:  Benita J Myles; Lee Ann Jarrett; Susan L Broom; H Anton Speaker; Karen E Sabol
Journal:  Psychopharmacology (Berl)       Date:  2008-04-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.